WO2003055995A3 - Lipase genes and proteins - Google Patents

Lipase genes and proteins Download PDF

Info

Publication number
WO2003055995A3
WO2003055995A3 PCT/CA2002/001998 CA0201998W WO03055995A3 WO 2003055995 A3 WO2003055995 A3 WO 2003055995A3 CA 0201998 W CA0201998 W CA 0201998W WO 03055995 A3 WO03055995 A3 WO 03055995A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
lipase
proteins
lpdlr
lpdl
Prior art date
Application number
PCT/CA2002/001998
Other languages
French (fr)
Other versions
WO2003055995A2 (en
Inventor
Xiao-Yan Wen
A Keith Stewart
Lap-Chee Tsui
Robert A Hegele
Original Assignee
Xiao-Yan Wen
A Keith Stewart
Lap-Chee Tsui
Robert A Hegele
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiao-Yan Wen, A Keith Stewart, Lap-Chee Tsui, Robert A Hegele filed Critical Xiao-Yan Wen
Priority to AU2002351616A priority Critical patent/AU2002351616A1/en
Priority to EP02787289A priority patent/EP1492873A2/en
Priority to CA002471119A priority patent/CA2471119A1/en
Publication of WO2003055995A2 publication Critical patent/WO2003055995A2/en
Publication of WO2003055995A3 publication Critical patent/WO2003055995A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Lipase proteins play important role in tissue or plasma lipid and lipoprotein metabolism and function to hydrolize lipid such as triglycerides. Disease associates with lipase function indludes lipase deficiency, atherosclerosis, fatty liver disease and dyslipidemias, such as hypercholesterolemia, hypertriglyceridemia, mixed (combined) dyslipidemia, lipid or lipoprotein deficient states, and/or any other tissue or plasma disorders of lipid or lipoprotein metabolism. The invention describes two novel lipase proteins (LPDL and LPDLR) and the nucleic acids encoding them as well as the regulatory sequences controlling their gene expression. The invention relates to use of LPDL and/or LPDLR nucleic acid or their proteins in modulating cellular process in disease state or in normal energy homeostasis. The invention also relate to their modulators, antibodies, antisense oligonucleotides and diagnostic assays, the screening for mutations, gene therapy, use of their promoters to control gene expression, and their industrial use in food industry and oil and waste management. The invention also relates methods of drug screening for LPDL and LPDLR, their therapeutic use in humans and their use as pharmaceutical compositions.
PCT/CA2002/001998 2001-12-21 2002-12-23 Lipase genes and proteins WO2003055995A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002351616A AU2002351616A1 (en) 2001-12-21 2002-12-23 Lipase genes and proteins
EP02787289A EP1492873A2 (en) 2001-12-21 2002-12-23 Lipase genes and proteins
CA002471119A CA2471119A1 (en) 2001-12-21 2002-12-23 Lipase genes and proteins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34178601P 2001-12-21 2001-12-21
US60/341,786 2001-12-21
US34660302P 2002-01-10 2002-01-10
US60/346,603 2002-01-10

Publications (2)

Publication Number Publication Date
WO2003055995A2 WO2003055995A2 (en) 2003-07-10
WO2003055995A3 true WO2003055995A3 (en) 2003-11-20

Family

ID=26992663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/001998 WO2003055995A2 (en) 2001-12-21 2002-12-23 Lipase genes and proteins

Country Status (4)

Country Link
EP (1) EP1492873A2 (en)
AU (1) AU2002351616A1 (en)
CA (1) CA2471119A1 (en)
WO (1) WO2003055995A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015141137A (en) * 2014-01-29 2015-08-03 国立大学法人大阪大学 Method for acquiring hdl derived from small intestine, method for evaluating hdl derived from small intestine, method for screening compound having action for increasing hdl derived from small intestine, and medicine for increasing hdl derived from small intestine and familial hypercholesterolemia therapeutic agent including the compound
CN106884008B (en) * 2015-12-16 2021-09-24 丰益(上海)生物技术研发中心有限公司 Phospholipase, coding gene and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057132A1 (en) * 1998-05-07 1999-11-11 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO2001057188A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2002024898A2 (en) * 2000-09-25 2002-03-28 Millennium Pharmaceuticals, Inc. 47647, a human lipase and uses therefor
WO2002031131A1 (en) * 2000-10-11 2002-04-18 Mochida Pharmaceutical Co., Ltd. Novel pla1
WO2002063005A2 (en) * 2001-02-06 2002-08-15 Incyte Genomics, Inc. Lipid-associated molecules

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057132A1 (en) * 1998-05-07 1999-11-11 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO2001057188A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2002024898A2 (en) * 2000-09-25 2002-03-28 Millennium Pharmaceuticals, Inc. 47647, a human lipase and uses therefor
WO2002031131A1 (en) * 2000-10-11 2002-04-18 Mochida Pharmaceutical Co., Ltd. Novel pla1
WO2002063005A2 (en) * 2001-02-06 2002-08-15 Incyte Genomics, Inc. Lipid-associated molecules

Also Published As

Publication number Publication date
AU2002351616A8 (en) 2003-07-15
EP1492873A2 (en) 2005-01-05
CA2471119A1 (en) 2003-07-10
AU2002351616A1 (en) 2003-07-15
WO2003055995A2 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
Delorme et al. Effects of surfactants on lipase structure, activity, and inhibition
WO2008043753A3 (en) Rna antagonist compounds for the modulation of pcsk9
AU5161800A (en) Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
ATE290403T1 (en) IMPROVEMENT OF NUCLEIC ACID ADMINISTRATION IN CELLS OF PLURICECELLULAR EUKARYOTIC ORGANISMS AND COMBINATION FOR PERFORMING THE PROCEDURE
Jones et al. Linking lipids to chromatin
WO2006037982A3 (en) Modulators of crth2 receptor activity for the treatment of prostaglandin d2 mediated diseases
MX9702204A (en) RIBOZYME TREATMENT OF DISEASES OR CONDITIONS RELATED TO LEVELS OF PLASMA LIPOPROTEIN (a) [Lp(a)] BY INHIBITING APOLIPOPROTEIN (a) [APO(a)].
Elangovan et al. Nano‐sized calcium phosphate particles for periodontal gene therapy
Zhang et al. High-yield and sustainable production of phosphatidylserine in purely aqueous solutions via adsorption of phosphatidylcholine on triton-X-100-modified silica
AU5799200A (en) Lpl variant therapeutics
Hakalin et al. Optimization of lipase-catalyzed synthesis of β-sitostanol esters by response surface methodology
EP1430072A4 (en) Antisense modulation of cholesteryl ester transfer protein expression
Salah et al. Biochemical and molecular characterization of a lipase produced by Rhizopus oryzae
WO2003055995A3 (en) Lipase genes and proteins
WO2001070993A3 (en) Polynucleotides that control delta-6-desaturase genes and methods for identifying compounds for modulating delta-6-desaturase
WO1998010076A3 (en) Phospholipase d and dna sequences
Srivastava et al. Rationalized insights on causes of rheumatoid arthritis in the elderly and women: special emphasis on treatment strategies
WO2005115461A3 (en) Pharmaceutical composition for modulating the activity of triglyceride hydrolase
EA200870059A1 (en) CHITINA DERIVATIVES FOR USE IN HYPERLIPIDEMIA
Kerner et al. Interplay in lipoplexes between type of pDNA promoter and lipid composition determines transfection efficiency of human growth hormone in NIH3T3 cells in culture
Kamoun et al. Biochemical characterization of Yarrowia lipolytica LIP8, a secreted lipase with a cleavable C-terminal region
WO2001055410A3 (en) Ceramidase compositions and methods based thereon
AU6113098A (en) Compositions for treatment of disorders involving programmed cell death
WO2001042424A3 (en) Sphingolipid-containing cationic liposomes for topical delivery of bioactive material
Jia et al. Production of l-α-Glycerylphosphorylcholine from Oil Refining Waste Using a Novel Cold-Active Phospholipase B from Bacillus velezensis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2471119

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002787289

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2113/DELNP/2004

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2002787289

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP